| Date | Title | Description |
| 23.12.2025 | Regulatory approval and a milestone payment for Swiss biotechs |
The European Commission has granted orphan designation in the European Union (EU) for Memo Therapeutics’ potravitug, a highly potent human BK polyomavirus (BKPyV)-neutralizing antibody for the treatment of BKPyV infection in kidney transpl... |
| 11.12.2025 | Aukera Therapeutics welcomes industry veteran as investor and board member |
Aukera Therapeutics is on the mission to develop novel therapies for diseases related to the protein mTOR (mammalian Target of Rapamycin) which regulates cell growth and metabolism. mTOR acts in the cell by forming two complexes, mTORC1 or... |
| 03.12.2025 | Four biotech startups reach key milestones |
MUVON Therapeutics AG, which is focused on the treatment of stress urinary incontinence (SUI) in women, has achieved positive topline results from the Phase 2 clinical trial SUISSE-MPC2 (NCT05534269) evaluating its novel proprietary muscle... |
| 15.10.2025 | Industry veterans join Lifesciences and fashion-tech startups |
MetaLead Therapeutics, a spinoff of the University of Zurich, has developed a novel metal-binding peptide platform to create best-in-class therapeutics that target pathological metals, restore healthy balance, or deliver therapeutic counte... |
| 17.09.2025 | Seasoned leaders step into key roles at life sciences startups |
Melodia Therapeutics, a Forty51 Ventures company, developing a next generation DPP1 inhibitor with best-in-class potential for inflammatory conditions, has appointed Jonathan Talbot as Chief Executive Officer. He brings over 15 years of in... |
| 30.06.2025 | Forbion Announces Fifth Exit from Forbion Growth Opportunities Fund II with the Sale of Capstan Therapeutics to AbbVie for USD 2.1 Billion | • Capstan sale ranks as the largest ever payment for an early-stage private biotech company by upfront consideration value and is Forbion’s seventh consecutive >$1B exit.
• Capstan’s in vivo CAR-T platform offers a first-in-class approac... |
| 06.05.2025 | Private biotech companies set new records |
During 2024, Switzerland’s biotech sector continued to demonstrate resilience despite significant financial and market challenges. Revenues remained strong at CHF 7.2 billion, while R&D investment grew to CHF 2.6 billion. Private biote... |
| 10.01.2025 | Numab Therapeutics: A Financial Surge in the Fight Against Cancer | In the world of biotechnology, where innovation meets investment, Numab Therapeutics has made headlines with its recent financial maneuvering. The Swiss company, known for its pioneering work in multi-specific antibodies, has successfully c... |
| 10.01.2025 | Numab Therapeutics raises $55M for antibody-based immunotherapies | Biotech Numab Therapeutics has raised $55 million, bringing its Series C fundraise to $197 million.
Numab is a clinical-stage company developing multi-specific antibody-based immunotherapies for inflammation and cancer.
Its developed a repr... |
| 09.01.2025 | Numab raises additional CHF50 million |
In 2024 Numab caused a stir with the acquisition of the biotech’s spin-out Yellow Jersey Therapeutics by Johnson & Johnson for $1.25 billion. Numab’s immuno-oncology therapeutic NM26 entered the clinic and the company started a collabo... |
| 09.01.2025 | Numab Therapeutics Announces Series C Extension to CHF 180 Million, Completing Oversubscribed CHF 50 Million Financing | CHF 50 Million extension round co-led by Cormorant Asset Management,
with participation from other existing investors
Proceeds will be used to support the advancement of multiple first-in-class and best-in-class programs into clinical devel... |
| 20.11.2024 | FDA approval and a key partnership to accelerate drug development |
The Fast Track Designation from the U.S. Food and Drug Administration (FDA) is aimed at accelerating the development and review process for drugs that address unmet medical needs, offering benefits like priority review, increased interacti... |
| 06.11.2024 | Biotech companies report progress in clinical trials |
Following the sale of its lead molecule NM26 to Johnson & Johnson for USD 1.25 billion in May, Numab Therapeutics announced the start of a Phase 1 clinical trial evaluating NM32, a next generation tri-specific immuno-oncology therapeut... |
| 15.10.2024 | Forbion raises in excess of €2 billion for two new funds | • Forbion’s largest fundraising to date, with Forbion’s Growth Opportunities Fund III raising €1.2 billion and Forbion Ventures Fund VII raising €890 million
• Assets under management now at €5 billion
• Fundraising follows strong performan... |
| 31.05.2024 | Forbion's Billion-Dollar Sale to Johnson & Johnson: A Landmark Achievement in Biotech Innovation | The recent announcement of Forbion's sale of Yellow Jersey Therapeutics to Johnson & Johnson for a staggering $1.25 billion has sent shockwaves through the biotech industry. This monumental deal, which includes the acquisition of rights... |
| 30.05.2024 | Numab Therapeutics' spin-off, Yellow Jersey Therapeutics, gets acquired by Johnson & Johnson for USD 1.25 billion | Numab Therapeutics' spin-off, Yellow Jersey Therapeutics, gets acquired by Johnson & Johnson for USD 1.25 billion 30.05.2024 10:06, Rita Longobardi linkedIn facebook twitter instagram youtube -->
Numab Therapeutics has agreed to sell... |
| 28.05.2024 | Ad hoc announcement pursuant to Art. 53 LRHBM portfolio company Yellow Jersey Therapeutics to be acquired for USD 1.25 billion | HBM Healthcare Investments (SIX: HBMN) today announced that Yellow Jersey Therapeutics, a portfolio company, has entered into an agreement with Johson & Johnson, whereby Johnson & Johnson will acquire global rights to NM26, a Phase ... |
| 28.05.2024 | Forbion Announces $1.25 Billion Sale to Johnson & Johnson of Numab Therapeutics Subsidiary, Including Rights to NM26, a Bi-specific Antibody for the Treatment of Atopic Dermatitis, Marking its Six... | • Forbion announces the sale of Yellow Jersey Therapeutics, a wholly owned subsidiary to be spun off from its portfolio company Numab Therapeutics, an investment of Forbion’s Growth Opportunities Fund I
• This is Forbion's sixth consecutive... |
| 28.05.2024 | Johnson & Johnson acquires Numab spin-off for USD 1.25 billion |
Numab Therapeutics AG based in Horgen (ZH) is developing multi-specific antibody-based immunotherapies for inflammation and cancer. Johnson & Johnson will acquire global rights to Numabs lead molecule NM26, a Phase 2-ready investigatio... |
| 20.10.2023 | Early-stage pharmaceutical companies make strides in cancer- and immunotherapy | |
| 15.05.2023 | Numab TherapeutIcs doses first patient with eczema | |
| 04.04.2022 | Numab signs a CHF 258 million deal with Ono Pharmaceuticles | |
| 20.05.2021 | Numab Therapeutics Completes CHF 100 Million Series C Financing | |
| 20.05.2021 | Numab Therapeutics completes oversubscribed CHF 100 million Series C financing | Numab Therapeutics completes oversubscribed CHF 100 million Series C financing 20.05.2021 17:35, Isabelle Mitchell linkedIn facebook twitter instagram youtube -->
Numab Therapeutics, a clinical-stage biopharmaceutical company developing ... |
| 20.05.2021 | Numab Therapeutics Completes Oversubscribed CHF 100 Million Series C Financing | Numab Therapeutics AG, a clinical stage biopharmaceutical company developing next-generation multispecific antibody-based immunotherapies for cancer and inflammation, today announced the closing of a CHF 100 million (approximately USD 110 m... |
| 20.05.2021 | Numab raises $111M to challenge Genmab, BioNTech for emerging PD-L1 opportunity | Numab Therapeutics has raised CHF 100 million ($111 million) to expand clinical development of its lead PD-L1x4-1BB drug candidate into multiple cancer indications. Novo Ventures and HBM Partners co-lead the series C round with assists from... |
| 20.05.2021 | Numab Therapeutics Completes CHF 100 Million Series C Financing | Numab Therapeutics aims to write the next chapter in cancer immunotherapy by creating multi-specific antibodies that enable the pursuit of novel therapeutic strategies. Its lead product was designed to balance potent anti-tumor immunity wit... |
| 13.01.2021 | Numab Therapeutics signs co-development partnership with Japanese Pharma | |
| 13.01.2021 | Numab Therapeutics signs co-development partnership with Japanese Pharma | Numab Therapeutics is an oncology-focused biopharmaceutical company is developing multi-specific antibodies that enable the pursuit of novel therapeutic strategies based on its proprietary MATCH technology platform. The company has a broad ... |
| 05.10.2020 | Startups win strong and well-connected board members | |
| 05.10.2020 | Startups win strong and well-connected board members | NBE Therapeutics, Erich Schlick, chairman of the board of Director
NBE-Therapeutics, a biotech company developing best-in-class cancer therapies based on its proprietary, highly differentiated Antibody Drug Conjugate (ADC) platform, announc... |
| 24.08.2020 | Numab Therapeutics advances to the clinical trials stage | |
| 24.08.2020 | Numab Therapeutics advances to the clinical trials stage | Numab Therapeutics is an oncology-focused biopharmaceutical company is developing multi-specific antibodies that enable the pursuit of novel therapeutic strategies based on its proprietary MATCH technology platform. Numab’s lead candidate, ... |
| 09.07.2020 | Boehringer Ingelheim to Develop Antibody Therapeutics with Numab | |
| 09.07.2020 | Boehringer Ingelheim to Develop Antibody Therapeutics with Numab | Numab Therapeutics and Boehringer Ingelheim today announced that they have entered into a research collaboration and worldwide licensing agreement. It will start with two projects aiming at novel therapies for difficult-to-treat lung and ga... |
| 30.03.2020 | Numab Therapeutics to receive additional CHF 260M from its Japanese partner | |
| 30.03.2020 | Numab Therapeutics to receive additional CHF 260M from its Japanese partner | The Zurich based Numab Therapeutics is focusing on the development of multi-specific antibodies based on its proprietary MATCH technology platform for the treatment of several cancers. The company’s lead oncology program ND021 was designed ... |
| 09.03.2020 | MUFG Capital joins Zurich-based Numab Therapeutics’ $22.6m Series B | Premium
Zurich-based biotech company Numab Therapeutics has snagged a total of $22.6 million in its Series B financing from a number of Asian investors as well as its board member, Dr. Daniel Vasella.
Continue reading this story with a subs... |
| 09.03.2020 | Vasella helps Numab to CHF22M round ahead of cancer trial start | Numab Therapeutics has raised CHF 22 million ($23.8 million) ahead of the start of clinical testing of its lead oncology drug ND021. Daniel Vasella, the former CEO of Novartis, was among the people to participate in the financing round.
Spo... |
| 09.03.2020 | Numab Therapeutics raises CHF 22M series B round | |
| 09.03.2020 | Swiss Biotech Numab Therapeutics raises CHF 22 million | Swiss Biotech Numab Therapeutics raises CHF 22 million 09.03.2020 15:38, Gianmaria Sbetta linkedIn facebook twitter instagram youtube -->
Numab Therapeutics announced today the closing of its Series B financing round at a total volume of... |
| 09.03.2020 | Numab Therapeutics raises CHF 22M series B round | Numab Therapeutics is an oncology-focused biopharmaceutical company developing a pipeline of multi-specific biotherapeutics in immuno-oncology and immunology for the treatment of severe diseases. With the new funds raised in a Series B roun... |
| 09.03.2020 | Mitsubishi joins Eisai, 3SBio's bet on multispecific antibodies, upping Numab's Series B haul to $23M+ | Following a busy year of dealmaking, Swiss antibody shop Numab has closed a Series B at CHF22 million ($23.87 million) to double down on its multispecific molecules for immuno-oncology and grow its team.
Daniel Vasella... |
| 09.03.2020 | Vasella helps Numab to CHF22M round ahead of cancer trial start | Numab Therapeutics has raised CHF 22 million ($23.8 million) ahead of the start of clinical testing of its lead oncology drug ND021. Daniel Vasella, the former CEO of Novartis, was among the people to participate in the financing round.
In ... |
| 17.12.2019 | Biotech Startup Numab Therapeutics Raises CHF 15 Series B Round | Biotech Startup Numab Therapeutics Raises CHF 15 Series B Round 17.12.2019 13:52, Gianmaria Sbetta linkedIn facebook twitter instagram youtube -->
Swiss Biotech company Numab Therapeutics has announced the closing of it's CHF 15 million ... |
| 13.12.2019 | A new partner and investor for Numab | |
| 16.10.2019 | Daniel Vasella joins biotech startup | |
| 01.10.2019 | Eisai teams up with Numab to generate cancer therapeutics | |
| 03.05.2019 | Numab signs licensing deal with Chinese biopharmaceutical company | |
| 15.09.2017 | Intarcia and Numab Reach Key Milestone | |
| 16.06.2017 | Numab achieves milestones and signs new partnerships | |
| 29.03.2017 | Profitable deal for Numab | |
| 09.06.2015 | Tillotts and Numab conclude license agreement | |
| 20.03.2015 | Intarcia and Numab to develop once-yearly therapies in diabetes, obesity and autoimmune indications | |
| 12.06.2014 | Milestone payment for Numab | |
| 30.10.2013 | Numab Reacquires Advanced Compound from Sucampo | |
| 25.10.2013 | CEO Day 2013: a huge and efficient event - updated | |
| 31.07.2013 | Robert Kamen Joins Numab’s Advisory Board | |
| 19.03.2013 | Numab Earns Milestone Payment from Sucampo | |
| 18.12.2012 | Numab Nominates Burkhard Becher Scientific Advisor | In 2003 Burkhard was recruited as Assistant Professor to the University Hospital of Zurich and in 2008, he became full professor and co-chair at the Institute of Experimental Immunology at the University of Zurich. His fundamental contribut... |
| 07.12.2012 | More start-ups than ever at the Swiss Venture Day | |
| 23.11.2012 | Eight promising start-ups present at the next Swiss Venture Day | |
| 20.06.2012 | CTI Start-up Label for Numab, Qvanteq, SwissTV and Virometix | |
| 12.06.2012 | Grow Wädenswil im Aufwärtstrend | |
| 06.02.2012 | Ex-Esbatech employees are building up a new company | |
| - | Numab | “numab, Drug Innovators, Swiss biotech company, development, antibody-based therapeutics, Swiss, biotech company, biotech, antibody, antibodies, antibody fragment, scFv, variable domain, Fv fragment, antibody discovery, antibody development... |
